BidaskClub lowered shares of Neurocrine Biosciences (NASDAQ:NBIX) from a buy rating to a hold rating in a research note published on Friday, BidAskClub reports.

Several other equities research analysts also recently issued reports on NBIX. Piper Jaffray Companies lifted their price objective on Neurocrine Biosciences from $103.00 to $111.00 and gave the stock an overweight rating in a report on Tuesday, July 30th. Oppenheimer started coverage on Neurocrine Biosciences in a report on Tuesday, July 16th. They set an outperform rating and a $100.00 price objective on the stock. Stifel Nicolaus set a $113.00 price objective on Neurocrine Biosciences and gave the stock a buy rating in a report on Monday, July 15th. Needham & Company LLC reiterated a hold rating on shares of Neurocrine Biosciences in a research report on Wednesday, July 31st. Finally, Credit Suisse Group lifted their target price on Neurocrine Biosciences from $95.00 to $110.00 and gave the stock an outperform rating in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Neurocrine Biosciences has a consensus rating of Buy and a consensus price target of $106.05.

NBIX stock opened at $97.80 on Friday. The company has a quick ratio of 7.32, a current ratio of 7.44 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $125.59. The stock’s 50 day moving average is $96.56 and its two-hundred day moving average is $86.35. The company has a market capitalization of $8.96 billion, a PE ratio of 444.55, a P/E/G ratio of 5.80 and a beta of 1.26.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, July 29th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.13. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The company had revenue of $183.58 million for the quarter, compared to the consensus estimate of $161.79 million. During the same period in the previous year, the business earned ($0.07) EPS. Neurocrine Biosciences’s revenue for the quarter was up 89.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Neurocrine Biosciences will post 0.68 EPS for the current year.

In related news, insider Haig P. Bozigian sold 7,220 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $87.63, for a total transaction of $632,688.60. Following the completion of the transaction, the insider now owns 149,096 shares in the company, valued at approximately $13,065,282.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Benevich sold 5,835 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $87.44, for a total value of $510,212.40. Following the transaction, the insider now owns 14,910 shares of the company’s stock, valued at approximately $1,303,730.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 181,461 shares of company stock valued at $17,157,806. Insiders own 4.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Treasurer of the State of North Carolina boosted its position in Neurocrine Biosciences by 6.0% during the 2nd quarter. Treasurer of the State of North Carolina now owns 61,421 shares of the company’s stock valued at $5,186,000 after purchasing an additional 3,450 shares during the period. Colony Group LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter valued at approximately $1,427,000. International Biotechnology Trust PLC boosted its position in Neurocrine Biosciences by 51.4% during the 2nd quarter. International Biotechnology Trust PLC now owns 156,800 shares of the company’s stock valued at $13,239,000 after purchasing an additional 53,200 shares during the period. Perceptive Advisors LLC boosted its position in Neurocrine Biosciences by 7.1% during the 2nd quarter. Perceptive Advisors LLC now owns 4,023,862 shares of the company’s stock valued at $339,734,000 after purchasing an additional 265,200 shares during the period. Finally, University of Notre Dame DU Lac acquired a new position in Neurocrine Biosciences during the 2nd quarter valued at approximately $3,908,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: Most Active Stocks

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.